Opinion

Video

DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

Author(s):

Edgardo S. Santos, MD, FACP, FCCP,Martin Dietrich, MD, PhD

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

Related Videos
Bertram Yuh, MD, MISM, MSHCPM
Nicolas Girard, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Idoroenyi Amanam, MD
5 KOLs are featured in this series.
Related Content
Noman Ashraf, MD, of Tampa General Hospital
October 24th 2024

2024 Regulatory Approvals Across NSCLC Propel the Therapeutic Landscape Forward

D. Ross Camidge, MD, PhD; Douglas Ney, MD, professor, neurology and neurosurgery, program director, Neurology Residency Program, vice-chair, Education, Department of Neurology, University of Colorado Cancer Center
October 23rd 2024

Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD

The OncFive
October 19th 2024

The OncFive: Top Oncology News and Trends for the Week of 10/13

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Myung-Ju Ahn, MD, PhD, professor, hemato-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
October 16th 2024

Osimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLC

FDA
October 15th 2024

FDA Approves Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy